Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Belite BioSTU:D01 +1.55%20 Current Ratio is 0.00 as of Mar. 2026. GuruFocus rates STU:D01 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Belite Bio ranks worse than 70871.65% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Belite Bio's current ratio for the quarter that ended in Mar. 2026 was 0.00.
Belite Bio has a current ratio of 0.00. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Belite Bio has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Belite Bio's Current Ratio or its related term are showing as below:
During the past 6 years, Belite Bio's highest Current Ratio was 50.02. The lowest was 10.66. And the median was 24.76.
STU:D01's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.88 * Ranked among companies with meaningful Current Ratio only.
Belite Bio (STU:D01) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Belite Bio Current Ratio Related Terms
Belite Bio Current Ratio Historical Data
* Premium members only.
The historical data trend for Belite Bio's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:D01 vs DFTX, LGND, XENE: Current Ratio Comparison
For the Biotechnology subindustry, Belite Bio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Belite Bio Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Belite Bio's Current Ratio distribution charts can be found below:
* The bar in red indicates where Belite Bio's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belite Bio (STU:D01) has a Current Ratio of 0.00 as of Mar. 2026. Over the past decade, Belite Bio's Current Ratio has ranged from 10.66 to 50.02. According to the industry distribution chart, Belite Bio ranks #999999 out of 1411 companies in the Biotechnology industry.
Is Belite Bio's Current Ratio too high?
Belite Bio's current Current Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 10.66 to a high of 50.02. Based on the distribution chart, Belite Bio ranks #999999 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Belite Bio has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's Current Ratio compare to DFTX and LGND?
According to the Biotechnology industry distribution chart, Belite Bio ranks #999999 out of 1411 companies for Current Ratio. This places Belite Bio in the lower half of its industry. The industry median Current Ratio is 3.88. Historically, Belite Bio's own Current Ratio has ranged from 10.66 to 50.02 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Belite Bio's current Current Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (STU:D01) has a current Current Ratio of 0.00. The current Current Ratio is 0.00. Belite Bio's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Belite Bio (STU:D01), the current Current Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
20GF Score
Get the complete analysis for STU:D01
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:D01 has been successfully added to your 
